The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519).
 
Maria Gonzalez
No Relationships to Disclose
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; AstraZeneca; AstraZeneca/UK; Aulos Bioscience; Bayer; BioNTech SE; Boehringer Ingelheim; Bristol Myers Squibb; Byondis; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics; Strand Therapeutics
 
Andrew Spillane
Speakers' Bureau - Lilly
 
Robyn Saw
Honoraria - Australian Clinical Laboratories; Merck Sharp & Dohme
Consulting or Advisory Role - MSD
 
Alexander Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Mark Faries
Consulting or Advisory Role - Merck; Novartis; Regeneron; Replimune
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Daiichi Sankyo/UCB Japan; Fortvita; IDEAYA Biosciences; Immunocore; IO Biotech; MSD; Natera; Novartis; Obsidian Therapeutics; Pfizer; Replimune; Scancell; Sun Pharma; T3 Pharmaceuticals; TriSalus Life Sciences; Veda Trials
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Linnaeus Therapeutics (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Replimune (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - AACR; Castle Biosciences; Immatics; Immunocore; IO Biotech; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; Sun Pharma; SWOG
 
Mario Mandala
Honoraria - Bristol-Myers Squibb/Sanofi; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron; Sanofi/Aventis
Consulting or Advisory Role - Bristol-Myers Squibb; LEO Pharma; MSD Oncology; Novartis; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Novartis (Inst)
 
Daniela Massi
Honoraria - AstraZeneca; Pierre Fabre; Regeneron; Sakura Finetek Japan; Sun Pharma
Consulting or Advisory Role - Regeneron; Sakura Finetek Japan; Sun Pharma
Research Funding - Regeneron
 
Andrew Barbour
No Relationships to Disclose
 
Julia Lai-Kwon
No Relationships to Disclose
 
Chi Kin Law
No Relationships to Disclose
 
Thomas Pennington
No Relationships to Disclose
 
Sydney Ch'ng
No Relationships to Disclose
 
Kerwin Shannon
No Relationships to Disclose
 
Robert Rawson
Honoraria - MSD
 
Monica Osorio
No Relationships to Disclose
 
Helen Rizos
No Relationships to Disclose
 
Serigne Lo
Consulting or Advisory Role - Skyline Diagnostics
 
Alexander van Akkooi
Consulting or Advisory Role - Adium Pharma; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly; Genmab; Menarini Silicon Biosystems; Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Regeneron; Replimune; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)